Citizens reiterates Globus Medical stock rating after Q1 beat By Investing.com

Globus Medical beat first-quarter 2026 expectations, with EPS of $1.12 versus $0.92 consensus and revenue of $759.9 million versus $740.3 million expected. Revenue rose 26% year over year in constant currency, or 11% excluding Nevro, while the company maintained sales guidance and lifted 2026 EPS guidance by about 7% at the midpoint. Analyst sentiment remained constructive, with Needham raising its target to $117 and Stifel to $95.

Analysis

The main signal here is not just a beat, but that GMED is proving it can grow through both core spine and adjacent technologies without needing an industry-wide volume tailwind. That matters because the stock should stop trading as a simple “Spine beta” name and start behaving more like a self-help compounder, especially if management keeps converting sequential execution into multiple guidance raises. The market likely still underestimates how much operating leverage sits in a business with high gross margins and a relatively fixed commercial footprint.

Second-order winners are likely the channel ecosystem and smaller competitors with weaker field-force economics. If GMED continues taking share in U.S. spine while expanding internationally, distributors and implant reps tied to slower-growth vendors will face pricing pressure and potential shelf-space loss; the real damage shows up in slower conversion of innovation into revenue, not in immediate headline share loss. The Nevro overhang is important because it creates an internal drag that can hide the strength of the core franchise, which means the stock may rerate only when investors believe the dilution is no longer masking underlying momentum.

The key risk is that this becomes a “good quarter, no multiple expansion” story if guidance credibility weakens or if the market rotates away from healthcare growth into rate-sensitive cyclicals. In the next 1-3 months, the main catalyst is whether management can sustain the 10% U.S. spine growth trend and convert broad-based demand into another upward revision cycle; over 6-12 months, the test is whether international growth and Enabling Tech can keep compounding enough to offset integration friction and any reimbursement noise. A miss on guidance cadence would hit the stock harder than a minor EPS wobble.

Consensus may be underpricing how quickly this can become a valuation re-rating candidate if execution remains clean. The current setup suggests the market is still anchored to the Nevro narrative and treating the company as partially challenged, when the more important read-through is that the core platform is accelerating with little sign of demand concentration. If that persists, the asymmetry shifts toward owning the name on pullbacks rather than chasing breakouts.

Key Decisions for Investors

• Buy GMED on any 3-5% post-print weakness over the next 1-2 weeks; target a 3-6 month rerating as investors re-anchor on core growth, with downside protected by continued earnings estimate revisions.
• Pair trade: long GMED / short a slower-growth spine peer over 3-6 months to isolate share-take and execution alpha; this should work if GMED keeps comping high single digits while the short leg remains growth-constrained.
• Sell cash-secured puts on GMED at strikes 8-12% below spot for the next earnings cycle; favorable if you want to be paid while waiting for the market to digest the Nevro overhang and guidance credibility.
• If you already own GMED, consider a call spread into the next catalyst window rather than outright shares; the thesis is multiple expansion from sustained revisions, not just incremental earnings upside.